Our Pipeline
A legacy of exploratory research continues
Continuous advancements for patients
For more than 30 years, we have pursued scientific discoveries that address unmet clinical needs. The process of developing biologics and small-molecule drugs draws on the expertise of many, inside and outside the organization. Together, we work to investigate new molecules that have the potential to change medicine and change lives.
3 FDA drug approvals
between 2018 and 2019
Notably, our work in pharmaceutical research and development has led to 3 FDA drug approvals between 2018 and 2019; two of these were recognized with breakthrough medicine status. Data on these medicines earned recognition as Best of ASBMR (2013), Best of ASCO (2016), and Best of ASH (2018).
Kyowa Kirin Pharmaceutical Pipeline
We collaborate with global teams and external partners to advance a robust pipeline of promising drug candidates.
Each candidate in our development pipeline reflects a ceaseless commitment to bring new medicines in the following therapeutic areas: neurology, immunology & allergy, oncology, nephrology, central nervous system (CNS), and rare disease. Many of our programs target diseases for which patients lack sufficient treatment options.
The clinical and safety profile of investigational drug candidates or investigational uses of approved medicines in the pipeline has not been established.
View the most current global Kyowa Kirin pipeline here
Clinical testing of novel compound drugs is a complex process with no guaranteed results. Our hope in pursuing these proposed indications is to deliver to patients the advances that may have a profound impact on their disease.
Innovative clinical trial design
With our clinical research, Kyowa Kirin aspires to contribute to the enhancement of medical care, the advancement of medical and pharmaceutical sciences, and the overall improvement of patients' health and well-being. We have accomplished the swift completion of registrational programs with innovative trial design by applying innovative methods for data capture and analysis.
Clinical trials enable our researchers to responsibly evaluate the safety and efficacy of potential treatments. These trials investigate new treatments in terms of efficacy and the presence of side effects. We are committed to publishing the results of our trials in peer-reviewed publications and in presentations at medical conferences around the world.
When engaging in clinical research, we give maximum consideration to the protection of the human rights and safety of patients who participate in the research. Furthermore, we strive to comply with relevant laws and regulations and to secure transparency in clinical research, scientific validity, independence, and reliability.
Kyowa Kirin Group Clinical Research Policy
We have established and are implementing the Kyowa Kirin Group Clinical Research Policy, which summarizes our approach to clinical research and code of conduct. Visit clinicaltrials.gov to learn about clinical research sponsored by Kyowa Kirin.
To learn about clinical trials sponsored by Kyowa Kirin, visit clinicaltrials.gov and enter “Kyowa Kirin” into the search field labeled, “Other Terms.”
Our expertise
Cross-functional teams help create and deliver innovative new medicines.
Transcript
Expanded access
Expanded access programs provide a process to make investigational treatments available to physicians with patients who face life-threatening diseases for which no approved therapy is available and who cannot participate in a clinical study. Kyowa Kirin North America welcomes inquiries about access to treatments that are currently in clinical studies.
Please review our policy for expanded access to unapproved drugs.
Partner with Kyowa Kirin.
